Skip to main content

Efficacy and Safety of a Polycaprolactone-Based Injectable Filler for the Correction of Mild-to-Moderate Chin Retrusion in Adults Compared with No Treatment: A Multicenter, Randomized Controlled Study

In brief

Polycaprolactone filler improved chin retrusion by one grade in 93% at 24 weeks

In a randomized trial of 162 adults, 93% of those treated with polycaprolactone filler improved by at least one chin-retrusion grade at 24 weeks, compared with none in the no-treatment group. Improvement was described through 60 weeks, but injection-site reactions were common, affecting 86% and usually mild and temporary; the trial did not compare filler with other treatments.

Journal
Aesthetic plastic surgery (Q1)
Published
15 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Chang Shu, Chenyu Zhu, Feng Li, Wei Du, Wei Wang, Xin Sun, et al.
PMID
43035579
DOI
10.1007/s00266-026-06332-x

Why clinicians should know about it

Abstract

BACKGROUND: Chin retrusion is a common aesthetic concern that disrupts lower facial balance. Polycaprolactone (PCL)-based injectable filler provides immediate volumization and stimulates endogenous collagen production, offering a nonsurgical approach to chin contour enhancement. METHODS: This multicenter, randomized, evaluator-blinded, no-treatment-controlled trial enrolled 162 adults with mild-to-moderate chin retrusion [Genial Chin Retrusion Scale (GCRS) grades 1-2]. Subjects were randomized 2:1 to PCL-based injectable filler treatment or no treatment. The primary endpoint was the proportion of GCRS responders, defined as improvement of at least one grade from baseline by blinded-evaluator assessment at Week 24. Secondary endpoints included GCRS response, Global Aesthetic Improvement Scale scores assessed by investigators and subjects, and subject-reported satisfaction through Week 60 in treated subjects and Week 24 in controls. Safety assessments included adverse events, injection-site reactions, and laboratory testing. RESULTS: At Week 24, GCRS response rates were higher in the PCL group than in the no-treatment control group (93.33% vs. 0%; difference, 93.33%; 95% confidence interval 84.07-96.73%; P < 0.001). Improvements in GCRS, investigator- and subject-rated Global Aesthetic Improvement Scale scores, and satisfaction were observed under trial conditions, with improvement in treated subjects maintained descriptively through Week 60. Injection-site reactions occurred in 85.71% of treated subjects and were predominantly mild and transient. Device-related treatment-emergent adverse events were infrequent. No serious device-related adverse events occurred. CONCLUSIONS: PCL-based injectable filler was effective and well tolerated for correcting mild-to-moderate chin retrusion compared with no treatment. These findings do not establish comparative effectiveness versus active treatments or clinical superiority. STUDY DESIGN: Prospective, multicenter, randomized controlled trial comparing the study product with no treatment. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.